SCHEMBL21145551

SCHEMBL21145551

CCC1CCN(C(C)C)C[C@@H]1C

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL26170333 1.00 — —
SCHEMBL14038216 1.00 — —
SCHEMBL26170436 1.00 — —
SCHEMBL25585003 0.85 CA1 (0.31) —
SCHEMBL21216997 0.84 — —
SCHEMBL23475114 0.82 HRH3 (0.31) —
SCHEMBL26889870 0.82 HRH3 (0.31) —
SCHEMBL26889899 0.82 HRH3 (0.31) —
SCHEMBL23435921 0.82 DPP4 (0.40) —
SCHEMBL20170518 0.82 DPP4 (0.40) —

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11186564-B2 Dual NAV1.2/5HT2a inhibitors for treating CNS disorders SUNOVION PHARMACEUTICALS INC. (US) 2021-11-30 — — US disclosed
US-20190194163-A1 DUAL NAV1.2/5HT2a INHIBITORS FOR TREATING CNS DISORDERS SUNOVION PHARMACEUTICALS INC. (US) 2019-06-27 — — US disclosed
Send feedback